Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo The fda approves eylea hd the treatment of patients with macular edema following retinal vein occlusion. Regeneron pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (cscc) who are at a high risk of recurrence following surgery and radiation.
Patel, md, discusses the fda approval of cemiplimab in cutaneous squamous cell carcinoma In a significant step forward for skin cancer management, the u.s The fda evaluated libtayo under priority review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions.
